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Background. Subsets of high grade endometrial cancer (EnCa) over-express HER2 (ERBB2), yet clinical trials
have failed to demonstrate any anti-tumor activity utilizing trastuzumab, an approved platform forHER2positive
breast cancer (BrCa). A truncated p95HER2 variant lacking the trastuzumab binding site may confer resistance.
The objective of this investigation was to characterize the expression of the p95HER2 truncated variant in EnCa.
Materials and methods.With institutional approval, 86 high grade EnCa tumors were identiﬁed with tumor
specimens from surgeries performed between 2000 and 2011. Clinical data were collected and all specimens
underwent tumor genotyping, HER2 immunohistochemistry (IHC, HercepTest®), HER2 ﬂuorescent in situ
hybridization (FISH), along with total HER2 (H2T) and p95HER2 assessment with VeraTag® testing. Regression
models were used to compare a cohort of 86 breast tumors selected for equivalent HER2 protein expression.
Results.We identiﬁed 44 high grade endometrioid and 42 uterine serous carcinomas (USC). IHC identiﬁed high
HER2 expression (2+ or 3+) in 59% of the tumors.HER2 gene ampliﬁcationwas observed in 16 tumors (12 USC, 4
endometrioid). BothHER2 gene ampliﬁcation andprotein expression correlatedwithH2T values. High p95HER2 ex-
pression above 2.8 RF/mm2 was observed in 53% (n = 54) with signiﬁcant correlation with H2T levels. When
matched to a cohort of 107 breast tumors based on HercepTest HER2 expression, high grade EnCa presented with
higher p95 levels (p b 0.001).
Conclusions. These data demonstrate that compared to BrCa, high grade EnCa expresses higher levels of
p95HER2 possibly providing rationale for the trastuzumab resistance observed in EnCa.© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).assachusetts General Hospital,
epartment of Obstetrics and
United States. Fax: +1 617 726
on).
. This is an open access article underIntroduction
Endometrial cancer (EnCa) is the most common gynecologic malig-
nancy in the United States [1]. While most women are cured, 15–20% of
patients will present with aggressive subtypes histologically charac-
terized as high grade endometrioid, uterine serous carcinoma (USC),
and carcinosarcoma that present with more advanced stage disease
that is commonly refractory to conventional platinum and taxane
based chemotherapy [2]. While these tumors account for a minority ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the 8000 deaths observed annually and innovative, targeted therapies
are needed to improve outcomes [3].
Ampliﬁcation of the HER2 gene and over-expression of the HER2 pro-
tein have been described in many human malignancies including breast,
colon, gastric, esophageal and endometrial and for some of these cancers,
anti-HER2 therapies have become a mainstay of treatment [4–6]. The
HER2 gene encodes a 185-kDa transmembrane tyrosine kinase receptor
and is located on chromosome17q21. HER2 is awell-characterizedmem-
ber of the human epidermal growth factor receptor superfamily that con-
sists of three other tyrosine kinase receptors (HER1/EGFR, HER3 and
HER4). Upon ligand binding, these receptors dimerize and induce signal
transduction through the mitogen-activated protein kinase (MAPK) and
phosphatidylinositol 3-phosphate (PI3K) signaling pathways. This down-
stream activation leads to induction of genes that promote oncogenic
transformation via cell survival, proliferation, angiogenesis andmetastasis
[7]. For women with HER2 over-expressing breast tumors, anti-HER2 di-
rected therapy has become a treatment platformwith numerous FDA ap-
proved therapies including trastuzumab, pertuzumab and lapatinib [8,9].
While HER2 over-expression was initially associated with the most
guarded prognosis in breast cancer (BrCa), the advent of a targeted anti-
HER2 therapy, has resulted in women with these HER2 positive tumors
having one of the most favorable prognoses [10].
Like BrCa, high grade EnCa, including high grade endometrioid, USC
and carcinosarcoma, has been shown to harbor a 10–42% rate of HER2
gene ampliﬁcation, with up to 70% of tumors exhibiting HER2 protein
over-expression [6,11,12]. Numerous studies have demonstrated HER2
over-expressing EnCa has been associated with decreased overall sur-
vival. Additionally, preclinical in vitro data has suggested that cells
derived from HER2 gene ampliﬁed USC tumors are more responsive
to anti-HER2 therapies compared to cells derived from non-
ampliﬁed tumors [13]. Despite promising preclinical data, the two
published phase II trials of anti-HER2 therapy in recurrent EnCa
manifested poor responses [14,15]. One trial evaluated single
agent lapatinib, a dual HER1/HER2 (ERBB1/ERBB2) inhibitor, and
found a 3% response rate, although these patients were not pre-
selected for HER2 over-expression [15]. Another recent phase II
trial pre-selected patients with HER2 over-expressing recurrent en-
dometrial tumors and administered the HER2 monoclonal antibody
trastuzumab. Unexpectedly, treatment revealed no responses [14].
Despite an extensive body of breast and gastric cancer literature
suggesting HER2 over-expression to be a biomarker for response
to anti-HER2 therapy, these targeted therapies failed to demon-
strate any activity in EnCa, even in a pre-selected population
enriched for HER2 over-expression. These trials suggest that single
agent therapies directed against HER2, even in the setting of gene
ampliﬁcation and/or protein over-expression, have limited effect,
possibly due to innate or drug induced resistance pathways.
Resistance to HER2 directed therapy is a common event in oncology,
particularly in BrCa [16]. Investigators have proposed many potential re-
sistance mechanisms including expression of a constitutively active
p95HER2 variant that results from either an alternative translational
start site or post-translational proteolysis that cleaves the HER2 extra-
cellular domain (ECD) [17,18] but preserves the intracellular tyrosine ki-
nase domain. Antibodies directed towards HER2, such as trastuzumab,
cannot bind in the absence of the ECD. Several retrospective analyses of
HER2 positive breast cancer found that increased p95HER2 expression
correlated with resistance to trastuzumab therapy and poor survival
[19,20]. Preclinical in vitro and in vivo studies demonstrated that
p95HER2 exhibited kinase activity that induced tumor proliferation that
was resistant to trastuzumab therapy [18,19,21]. As result of these obser-
vations, the p95HER2 variant is being actively investigated a biomarker
for trastuzumab resistance in prospective randomized trials incorporating
anti-HER2 therapies [22].
Similar to trastuzumab resistant BrCa, high grade endometrial tumors
appear to manifest innate anti-HER2 resistance growth patterns.Numerous investigations have demonstrated that endometrial tumors
harbor a high rate of PI3K pathway activation via PIK3CA gene mutation
and PTEN inactivation which would act to uncouple anti-HER2 blockade
[23,24], but the presence of the described truncated p95HER2 variant in
high grade EnCa is currently unknown. The purpose of this investigation
was to evaluate p95HER2 levels utilizing the novel VeraTag™ technology
[19] in a cohort of high grade EnCa and correlate these ﬁndings with total
HER2 expression, HER2 gene ampliﬁcation, tumor genotype and clinical
outcomes. In addition,we sought to understand if the p95HER2 landscape
observed in BrCa is different from that of high grade EnCa.
Materials and methods
Patients and samples
Following internal review board approval, we identiﬁed a cohort
of 86 high grade EnCa samples diagnosed between 2000 and 2011
with available tissue for analysis. Clinical factors were extracted
from patient records, including age, grade, stage, treatment, recur-
rence and survival. All molecular analyses were carried out on
formalin-ﬁxed and parafﬁn-embedded (FFPE) diagnostic specimens.
Hematoxylin and eosin-stained slides were marked for tumor loca-
tion by a gynecologic oncology pathologist.
A separate set of 86breast carcinomaswas identiﬁed andmatched to
the endometrial samples based on HercepTest® score and used as a
comparison group to understand the differences in continuous HER2
and p95HER2 protein expression generated by the VeraTag assays.
Immunohistochemistry
Parafﬁn embedded high grade EnCa and BrCa tissue sections of 5
μm thickness were subjected to immunohistochemistry (IHC) for
HER2 using the HercepTest (Dako, Carpinteria, CA), following the
manufacturer's recommendations. The intensity and pattern of the
HER2 membrane immunostaining were evaluated, and all samples were
scored by a pathologist on a 0–3+ scale with 0 representing no staining,
1+ representing weak staining in N10% of invasive tumor cells, 2+
representingmoderate intensity in N10%of invasive carcinoma cells or in-
tense staining in b10%, and 3+ staining deﬁned as intense circumferen-
tial membranous staining in N10% of the invasive carcinoma. One USC
sample was a technical failure for HercepTest staining and was therefore
excluded from analyses incorporating HercepTest stratiﬁcation.
Fluorescence in situ hybridization
To determine the HER2 gene copy number of the high grade EnCa
samples, ﬂuorescence in situ hybridization (FISH) was performed on
5 μm thick tissue sections. A PathVysion HER2 DNA Probe Kit (Abbott
Laboratories, Abbott Park, IL) was used, consisting of an LSI HER2
probe with SpectrumOrange label and a CEP 17 control probe with a
SpectrumGreen tag directed against the centromere region of chromo-
some 17. Counterstaining was carried out using Vectashield mounting
medium with 4,6-diamidino-2-phenylindole (DAPI) (Vector Laborato-
ries). All samples were visualized and scored using the CytoVision®
platform (Leica Biosystems, Buffalo Grove, IL). For each specimen, the
HER2 to CEP 17 ratio was determined by counting the red (HER2) and
green (CEP 17) signals in a minimum of 50 nuclei. Samples with a
HER2 to CEP 17 ratio greater than 2.0 were considered ampliﬁed. A
total of 2 samples (1 USC, 1 endometrioid) were technical failures of
the assay following triplicate attempts.
Tumor genotyping
An adapted version of the Applied Biosystems (ABI) Prism SNaPshot
multiplex system was used to genotype 3 mm core samples from N80%
tumor cells from primary FFPE tumors. Total nucleic acids were extracted
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FormaPure System (Beckman Coulter Genomics, Danvers, MA) on a
BeckmanCoulter BiomekNXPworkstation. This clinicalmutational proﬁl-
ing platform screens for 130 well-characterized mutations that are dis-
tributed across 15 cancer genes including AKT1, APC, BRAF, CTNNB1,
EGFR, ERBB2, IDH1, KIT, KRAS,MAP2K1, NOTCH1, NRAS, PIK3CA, PTEN, and
TP53 [25].
Quantitative HER2 assay
Total HER2 protein expression (H2T) was quantiﬁed using the
HERmark® assay as previously described [26,27] in the entire 86
tumor cohort. H2T was quantiﬁed through the release of a ﬂuorescent
tag conjugated to a HER2 monoclonal antibody (mAb) via a linker that
is sensitive to singlet oxygen. The antibodywas pairedwith a biotinylat-
ed second HER2 mAb. An avidin-linked photosensitizer molecule pro-
duces singlet oxygen upon illumination with red light. Fluorescence,
quantiﬁed by capillary electrophoresis, was normalized to the invasive
tumor area on the FFPE tissue section to give ﬁnal units of relative ﬂuo-
rescence/mm2 tumor (RF/mm2). Total HER2 (H2T) measurements in
FFPE BrCa tissues were compared to pre-speciﬁed cutoffs for HERmark
negative (H2T b 10.5 RF/mm2) and HERmark positive (H2T N 17.8 RF/
mm2) with equivocal deﬁned as 10.5 RF/mm2 ≤ H2T ≤ 17.8 RF/mm2,
derived from the b5th percentile of centrally determined HER2-
positives and the N95th percentile of centrally determined HER2-
negatives, respectively, within a reference database of 1090 breast
cancer patient samples. H2T N 10.5 RF/mm2 deﬁned the primary cutoff
value for elevated H2T expression in our endometrial samples.
Quantitative p95HER2 assay
P95HER2 (p95)was quantiﬁedusing theVeraTagplatformwith a pro-
prietary mAb speciﬁc for the active M611-CTF form of p95 as previously
described [19]. Brieﬂy, the bound p95 antibody is detected by an anti-
mouse secondary antibody which was conjugated a ﬂuorescent tag via a
linker that is sensitive to reduction by dithiothreitol (DTT). Following re-
lease by DTT, the ﬂuorescence signal was quantiﬁed as described above.
p95 ≥ 2.8 RF/mm2 was used to deﬁne “high” p95 protein expression as
this value has been associated with trastuzumab resistance in BrCa [19].
Statistical analysis
Two-sided Fisher's exact tests andχ2wereutilized to comparepropor-
tions for univariate analysis. Correlation was assessed utilizing Pearson
correlation and Spearman rank sum testing as appropriate. Continuous
variables were compared utilizing t-tests and linear regression models.
Kaplan–Meier survival estimateswere generated fromdate of histological
diagnosis to time of last follow-up or death, across the subgroup diag-
nosed with invasive disease. Log-rank tests were utilized to determine
statistical signiﬁcance of survival curves. A Cox proportional-hazards
model, incorporating signiﬁcant variables on univariate survival analysis,Table 1
Cohort characteristics.
USC
(n= 42)
Endometrioid
(n= 44)
Total
(n= 86)
Age (ave) 68.7 65.6 67.1
Stage
I 17 22 39
II 1 2 3
III 12 12 24
IV 11 8 19
Progressive disease
Yes 9 6 15
No 33 38 71
OS (years) 2.2 4.0 2.9was utilized to identify independent factors associated with overall sur-
vival (OS). An α b 0.05 deﬁned statistical signiﬁcance. Analysis was per-
formed on STATA version 10.0 (College Station, TX).
Results
Clinical characteristics
We identiﬁed 42 USC and 44 high grade endometrioid carcinomas.
The average age of the cohort was 67 with 50% of cases representing
stage III and IV disease (Table 1). Median overall survival was 2.9 years.
No signiﬁcant differences in age, stage or OS were observed between
the USC and endometrioid cohorts. Increased age at diagnosis, stage and
residual disease were signiﬁcantly associated with a worsened OS upon
univariate analysis. A Cox proportional hazards model incorporating all
these variables conﬁrmed that stagewas the only variable that associated
with worsened OS with a HR 3.43 (p= 0.01, 95% CI 1.25–2.24).
Tumor genotyping
The most prevalent mutations detected in this entire cohort were in
PIK3CA (16%), TP53 (14%), KRAS (7%) and PTEN (7%). No differences
were observed in the mutational proﬁle based on histologic subtype,
(Fig. 1), though we did note a trend towards a higher incidence of TP53
mutations in USC (p= 0.07). HER2 over-expressing samples deﬁned as
2+ or 3+ by Herceptest IHC, and p95HER2 over-expressing samples de-
ﬁned as RF/mm2 N 2.8 showed no difference inmutational proﬁles.While
mutations in PIK3CA, KRAS and PTEN did not associate with OS, mutations
in TP53were associated with a signiﬁcantly worsened OS (p= 0.02).
HER2 protein and gene expression
HercepTest IHC revealed high HER2 expression (2+ or 3+) in 59% of
the cohort (n= 51) with the remainder manifesting low (0 or 1+) ex-
pression (n= 34). HER2 gene ampliﬁcation was observed in 19% of the
cohort (n= 16); however the USC samples accounted for a signiﬁcant
majority when compared to the endometrioid set of samples (n = 12,
29% vs n=4, 9%, p=0.03). Gene ampliﬁcationwas associatedwith ame-
dian overall survival of 1.4 years, and this was not statistically different
from the 3.6 years observed in the non-ampliﬁed cohort (p= 0.07).
In the high grade EnCa samples, the HERmark assay characterized
HER2 protein expression as a continuous variable showing a signiﬁcant
positive correlation between HercepTest and HERmark scores (rho =
0.42, p b 0.001). Similarly, gene ampliﬁed samples were signiﬁcantly
associated with high HERmark scores (p = 0.002) (Fig. 2A). An
H2T ≥ 10.5 RF/mm2 score identiﬁed signiﬁcantly fewer cases (n= 20,
23%) when compared to the 2+ or 3+ HercepTest result (n = 50,
58%). Elevated HER2 protein expression deﬁned as 2+ or 3+ stainingFig. 1. Frequency of mutations in driver genes detected in the high grade EnCa cohort.
The SNaPshot® platform was used to test each high grade EnCa tumor sample. No
difference in the mutational proﬁle of USC, high grade endometrioid, HER2 or p95HER2
over-expressing samples was detected.
Fig. 2. Box plots and scatterplots demonstrating relationship between HER2 gene
ampliﬁcation, total HER2 and p95HER2 protein expression. The double red lines delineate
the HERmark negative, equivocal and positive zones which align with centrally
determined HER2 status in BrCa as described in Methods. Panel A demonstrates
that HER2 gene ampliﬁcation was associated with a signiﬁcantly higher H2T score (p b
0.002). Panel B displays the H2T and p95HER2 values, with the red triangles representing
the HER2 gene ampliﬁed samples. The red line at p95HER2 = 2.8 RF/mm2 is the cutoff
value associated with trastuzumab resistance in BrCa. HER2 gene ampliﬁcation was not
associated with p95HER2 values.
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mutation (p= 0.4). Both high grade endometrioid and USC presented
with similar HERmark score distributions (p= 0.79) (Fig. 3A).
p95HER2 expression in high grade EnCa
The VeraTag platform revealed that p95HER2 expression ≥ 2.8 RF/
mm2 was observed in the majority of the tumor samples tested (n =
46, 53%) (Fig. 2B).While p95HER2 andH2T demonstrated positive asso-
ciation (Spearman rho= 0.34), high p95 expressionwas not associated
with HER2 gene ampliﬁcation (Fig. 2B). Both high grade endometrioid
and USC presented with similar p95HER2 score distributions (p =
0.50) (Fig. 3B). No association of p95HER2 expression and survival out-
comes was observed.
Differential expression of p95HER2 and H2T in endometrial and
breast carcinoma
HERmark testing of 86 breast carcinoma samples matched to the
endometrial cohort by HercepTest scores revealed that H2T levels
were not statistically different from the 86 endometrial samples, evenFig. 3. Boxplots depicting theH2Tandp95HER2 scores of thehighgrade endometrioid, USC andBrC
werematchedbyHercepTest score. In this setting of equivalentH2T scores, Panel B demonstrates h
p95HER2 expression (both p b 0.001). Panels C and D depict the p95HER2 expression proﬁles of t
either HER2 IHC 3+orHER2 FISH-positive. HER2 negativewas deﬁned as HER2 IHC 0 or 1+orHE
Endometrioid) were HER2 IHC 2+, FISH-unknown and were not included in 3C or 3D. One USC cwhen stratiﬁed by histology (Figs. 3A, 4). Despite similar levels of
HER2 expression as measured by HercepTest and H2T levels, however,
the endometrial samples presented with signiﬁcantly elevated
p95HER2 levels when compared to those of the BrCa cohort (p b
0.001), and this relationship remained constant when subset analysis
of cohorts with and without HER2 over-expression were performed
(Fig. 3C and D). Scatter plots of p95HER2 vs. H2T expression conﬁrmed
that at every level of baseline H2T expression, a higher p95 expression
manifests, with themost statistically robust effects seen in the USC sub-
set (Fig. 4). To conﬁrm a cellular localization pattern consistent with
breast carcinoma p95HER2 [21], p95HER2 IHC was performed with
high grade EnCa tumor samples (Fig. 5). The p95HER2 staining intensity
representative of IHC 0–3+ is observed, with intense circumferential
membranous staining observed with IHC 3+ samples, consistent with
the staining pattern in breast carcinoma cells [19].
Discussion
These data demonstrate that across all levels of total HER2 expres-
sion, endometrial tumors present with innate elevation in p95HER2
expression when compared to breast tumors. While exploratory, these
data may provide rationale for the differential responses observed
when women with BrCa and EnCa were treated with trastuzumab.
Our genotyping results in EnCa highlight that gain of functionmutations
in PIK3CA and KRAS that could act to uncouple trastuzumab action, do
not appear to affect a disproportionate number of the HER2 positive
subset. These data highlight that in high grade EnCa, both gain of func-
tionmutation in PIK3CA and expression of the p95HER2 variant are like-
ly to be of importance in modifying response to trastuzumab.
Trastuzumab has been a mainstay of treatment for HER2 positive
(over-expressing and/or gene ampliﬁed) BrCa [10]. Numerous investi-
gators have identiﬁed HER2 over-expression or gene ampliﬁcation in
other cancers, such as gastric, esophageal, ovarian and endometrial [4,
5]. Despite the hope that any HER2 positive tumor will respond to
trastuzumab therapy, clinical trial results in other disease sites have
failed to produce clinical beneﬁt as robust as that demonstrated in
BrCa [28–30]. EnCa is emblematic of this challenge. The clinical trial test-
ing trastuzumab therapy in HER2 positive recurrent EnCa demonstrated
no responses, suggesting that HER2 over-expression is not the sole pre-
dictor of response [14]. Investigators attempted to rationalize the nega-
tive results by suggesting the test population lacked large numbers of
USC and HER2 gene ampliﬁed tumors [31]. Given the complete lack ofa samples. Panel A conﬁrms that theHERmarkH2T scores are not statistically different as they
owboth theUSCandhighgrade endometrioid samples harbor signiﬁcantly increased levels of
he HER2 positive and negative breast and endometrial cohorts. HER2 positive was deﬁned as
R2 IHC 2+/FISH non-ampliﬁedor HER2 IHC 2+/FISH non-ampliﬁed. Four cases (3 BrCa and 1
ase had neither HER IHC nor FISH results and was not included in 3C or 3D.
Fig. 4. Scatterplots depictingH2T andp95HER2 expression levels observed in theUSC, high grade endometrioid and total high grade EnCa cohort in comparison to a cohort of BrCamatched
for HER2 protein expression using the HercepTest. Red circles represent EnCa samples with best ﬁt line in red; black circles represent BrCa samples with best ﬁt line in black. Panel A
represents the USC samples only, with panel B depicting the high grade endometrioid only and panel C demonstrates the entire EnCa cohort simultaneously with the BrCa samples.
At every H2T level of expression, the EnCa samples harbor an elevated p95HER2 expression level.
164 W.B. Growdon et al. / Gynecologic Oncology 137 (2015) 160–166response, one must consider that EnCa may present with innate
trastuzumab resistance and that additional therapies, such as conven-
tional cytotoxics are required in concert with HER2 blockade to induce
anti-tumor effects. While any negative trial is disappointing, they do
offer the opportunity to understandwhy therapies failed to be effective,
and possibly shed light on how best to overcome resistance and affect
more durable responses.
In BrCa, trastuzumab resistance has been linked to loss of PTEN func-
tion and gain of function mutations in downstream signaling proteins,
such as PIK3CA [16]. Endometrial cancer harbors the most frequent al-
terations in the PI3K pathway of any solid tumor, making this an attrac-
tive candidate to explain the observed clinical resistance [24]. Echoing
more comprehensive genomic analyses [24], our investigation con-
ﬁrmed that HER2 expression did not correlate with the presence of
gain of function mutations suggesting that additional factors contribute
the observed resistance. One promising factor characterized in breast
tumors that led to a plausible explanation of treatment failure was ex-
pression of the p95HER2 truncated variant that lacks the ECD required
for trastuzumab binding. Expression of p95HER2 in BrCa diminished
sensitivity to trastuzumab in vitro, and was associated with reduced
clinical response to trastuzumab with a subsequently decreased sur-
vival [19,21]. Using the VeraTag technology, this investigation demon-
strates that a signiﬁcant proportion of high grade EnCa exhibited
elevated p95HER2 as deﬁned by a threshold associated with tras-
tuzumab resistance in BrCa [20]. While this is the ﬁrst report to cha-
racterize p95HER2 expression in high grade EnCa, these data are
consistent with another investigation that demonstrated that HER2“3+” “2+”
> 2.8 RF/mm2
Fig. 5. Representative p95HER2 IHC utilizing VeraTag antibody. Representative sections of 0,
The p95HER2 VeraTag assay utilized a continuous measurement of relative ﬂuorescence per s
and was used as the cutoff for elevated p95HER2 expression as this is the level that was associover-expressing USC cell lines shed HER2 ECD in vitro leading the
authors to conclude that response to therapy could be associated with
the degree of cleaved ECD [32]. When the p95HER2 and full length
HER2 expression proﬁles in high grade EnCa were compared to breast
tumors matched by the most widely used HER2 IHC test in the clinical
setting (HercepTest), the p95HER2 levels in endometrial tumors were
signiﬁcantly higher. These data suggest the HER2 landscape is funda-
mentally different in EnCa compared to BrCa and possibly predisposes
these tumors to innate trastuzumab resistance.
Although HER2 over-expressing endometrial tumors, particularly
USC, have been associated with aggressive disease and worsened sur-
vival in numerous investigations [6,33], expression of the p95HER2 var-
iant did not correlate with important clinical factors, such as stage and
survival. In the breast literature, p95HER2 status has been shown to
have prognostic value because those patients who had been treated
with trastuzumab in the metastatic setting had been shown to be
more refractory [19]. In our cohort of endometrioid and USC tumors,
no patients received trastuzumab or any anti-HER2 therapies making
conclusions about the p95HER2 contribution to survival or response to
therapy difﬁcult to assess. Given that p95HER2 expression is likely to
be a factor conferring resistance to anti-HER2 therapies that target the
ECD of HER2, one could hypothesize that the presence or absence of
elevated p95HER2 expression would not be related to clinical response
or OS unless trastuzumab therapy was a major part of the therapeutic
strategy.
This investigation conﬁrms a signiﬁcant body of literature that has
found HER2 over-expression and gene ampliﬁcation to be prevalent“0”“1+”
< 2.8 RF/mm2
1+, 2+ and 3+ IHC staining demonstrate the speciﬁcity of the membranous staining.
quare mm of tumor (RF/mm2). A value of N2.8 RF/mm2 corresponds to 2 or 3+ intensity
ated with trastuzumab resistance based on a retrospective cohort of breast tumors [19].
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ﬁcation was signiﬁcantly higher in USC compared to the endometrioid
tumors, both histologies exhibited similar HERmark total HER2 expres-
sion. Numerous studies have supported that HER2 is a promising target
for the treatment of endometrial tumors not curable with surgery or
radiation [35], the majority of which are high grade EnCa. The general
conclusion of these studies is that tumors harboring HER2 protein
over-expression with concurrent gene ampliﬁcation will likely be the
most responsive to anti-HER2 therapies [36]. Unfortunately, the avail-
able clinical data do not yet provide support for this rational position.
The addition of this p95HER2 data offers new insight into the HER2
landscape of these high grade endometrial tumors and provides ratio-
nale for a therapeutic strategy that utilizes dual anti-HER2 therapy
with two agents so that both the ECD and intracellular domain (ICD)
can be targeted [37]. This concept has gained traction in the BrCa litera-
ture leading some investigators to hypothesize that dual anti-HER2
therapies could replace cytotoxic chemotherapy for a signiﬁcant subset
of patients [38,39]. Currently, this concept is untested in EnCa, but pre-
clinical models utilizing USC non-immortalized cell lines and patient
derived xenografts supported an approach of combining trastuzumab
with lapatinib [40].
This molecular investigation of HER2 expression supports that a sig-
niﬁcant subset of high grade EnCa presents with elevated expression of
the p95HER2 variant when compared to breast carcinomasmatched for
equivalent HER2 protein expression. As p95HER2 has been associated
with trastuzumab resistance, this alteration may contribute to the tras-
tuzumab resistance observed in pre-clinical studies, as well as in the
clinical trial setting [20]. Several breast carcinoma trials are actively val-
idating p95HER2 levels as a biomarker associated with resistance to
anti-HER2 therapies. Early reports have described that the addition of
conventional cytotoxic chemotherapy can act to stabilize full length
HER2 and re-sensitize tumors to trastuzumab [20,22]. These ﬁndings
validate the ongoing randomized phase II trial in EnCa of conventional
carboplatin and paclitaxel therapy with or without trastuzumab
(NCT01367002). Given the elevated p95HER2 levels in high grade
EnCa compared to BrCa, p95HER2 expressionmay be of equal or greater
importance as a biomarker as investigators design and conduct future
trials in high grade EnCa that test the anti-HER2 therapies.Financial support
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